Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Treatment with the immunosuppressive drug mycophenolate mofetil (MMF) may result in
gastrointestinal (GI) complications in some patients. This study will assess if a switch from
MMF to enteric-coated mycophenolate sodium (EC-MPS) results in improved GI and/or
health-related quality of life in liver transplant recipients